BioSight
Back
Kodiak Sciences Inc. logo

KOD

NASDAQPALO ALTO, CA
Kodiak Sciences Inc.

Kodiak Sciences is a clinical-stage ophthalmology company developing monoclonal antibodies and bispecific therapies using its proprietary Antibody Biopolymer Conjugate platform for retinal diseases. The company's lead program, tarcocimab tedromer (Zenkuda), is an anti-VEGF monoclonal antibody that has completed Phase 3 studies in diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration, with a Phase 3 DAYBREAK study in wet AMD expected to report results in 3Q 2026. Kodiak is also advancing KSI-501, a bispecific anti-IL-6/VEGF-trap therapy in Phase 3 for wet AMD, and KSI-101, a bispecific anti-IL-6/VEGF protein in clinical development for

Price history not yet available for KOD.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.